Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca posts 6% rise in Q3 sales
Operating profit in the third quarter was $2.02 billion, down 7%. Operating profit was reduced by restructuring costs of $146 million and by $212 million from the inclusion
Operating profit in the third quarter was $2.02 billion, down 7%. Operating profit was reduced by restructuring costs of $146 million and by $212 million from the inclusion
The results are consistent with the large safety database already accumulated on the individual constituents fluticasone and formoterol. The study involved 472 patients who were treated with Flutiform
The study is a single-center, randomized, placebo-controlled, double-blind, parallel group assessment of the multiple-dose efficacy of ibuprofen 600mg ER, enrolling approximately 150 patients. The primary objective is to
The trial was part of a National Cancer Institute funded cooperative group study conducted by the Children’s Oncology Group (COG). The data is based on long-term follow up
The objective of this trial is to generate proof-of-concept data to evaluate the efficacy and safety, including neuropathy, of picoplatin in combination with 5-fluorouracil (5-FU) and leucovorin, Folpi
The Phase Ib, open-label single-arm clinical trial is expected to enroll up to 40 relapsed or refractory multiple myeloma patients at multiple sites in the US. Patients will
Under the terms of the agreement, Neurocrine will receive an initial payment of $20 million and an additional $10 million payment upon FDA approval of indiplon. Neurocrine is
Lansoprazole is used to treat gastrointestinal diseases including acid reflux and ulcers and is marketed under the trade name Prevacid in the US by TAP and in Europe
The company says Generex Oral-lyn is the first non-injectable buccalinsulin approved in India. In connection with the approval, Generex has entered into a product licensing and distribution agreement
The new drug application (NDA) contains data from six clinical studies in which over 400 patients received at least one dose of Nebido, with over 300 of these